quote:

bioscience schreef op 2 oktober 2014 10:42:

Overigens begrijp ik Lord niet .hij is ook actief op Het Genfit forum .
Dan moet hij weten dat Genfit vorig jaar lang rond de 4 heeft geschommeld . 1 jaar later staat Genfit 40 euro = + 1000 %
Zo snel kan het dus gaan . Zou maar zorgen dat je MDX in portefeuille hebt voor de komende jaren . Niet voor een dubbeltje op de eerste rang willen zitten

quote:

sam en moos schreef op 2 oktober 2014 16:19:

AEX duikelt behoorlijk met bijna 2% op één dag naar beneden en USA zal wel volgen na sluiting beurzen in Europa denk ik. Ze houden de boel nu nog aardig droog.
Heb voor de zekerheid een deel van alle aandelen verkocht (helaas), maar als daling morgen doorzet, grote kans dat de paniek toeslaat, zeker nu ook de F-26 gaan vertrekken en NL in oorlog is. Wat is dan de bodem?? Ik stap liever weer in als stijging komt, dan rusteloze nachten en slapeloos weekend.

quote:

vreemd vermogen schreef op 2 oktober 2014 22:45:

bradyurology.blogspot.nl/2014/09/a-ne...

A New Test May Change the Meaning of a “Negative” Prostate Biopsy

Nearly one million men undergo prostate biopsy yearly in the US. 750,000 (3 in 4) of these biopsies are histologically found to be negative for evidence of prostate cancer by microscopic analysis. Other data suggest that of these 750,000 negative biopsies, 25% (187,000) actually have cancer in the prostate that the initial biopsy might have missed. A new tissue assay (made by ConfirmMDx)

From MDxHealth.com looks at the methylation (alteration of the DNA) of three genes to predict that cancer may have been missed and that a repeat biopsy should be recommended. The test relies on the concept that a "halo" of DNA-alterations (methylation) occurs around a foci of cancer within the prostate. With the ability to search for DNA-abnormalities in the "halo," this test effectively increases the size of each biopsy and decreases the likelihood of missing a prostate cancer.

Jonathan I. Epstein, MD
The multicenter DOCUMENT (Detection of Cancer Using Methylated Events in Negative Tissue) study was conducted with 350 PSA-screened men from five major urologic centers, including Johns Hopkins University, Cleveland Clinic Foundation, Lahey Clinic, University of California Los Angeles and East Virginia Medical School. The study involved patients with an initial negative index prostate biopsy who had high-risk variables (e.g. High Grade PIN, Atypia high PSA, etc…) and compared this tissue methylation assay results to cancer detection in subsequent repeat biopsy within 24 months. Index and repeat biopsy tissues were subjected to blinded, centralized pathology review by Jonathan Epstein, MD, Reinhard Professor of Urologic Pathology and Director of Surgical Pathology at Johns Hopkins. The ConfirmMDx for Prostate Cancer test, was used to analyze the DNA from 3,687 negative tissue cores from the index prostate biopsy for epigenetic abnormalities. The study confirmed the previously published results using the same ConfirmMDx for Prostate Cancer test as a significant, independent predictor (odds ratio = 2.85) for the risk of prostate cancer in a repeat biopsy, outperforming standard clinical risk factors such as age, prostate specific antigen (PSA), digital rectal exam (DRE), and pathology in multivariate logistic regression analysis. In addition, the high negative predictive value of the epigenetic assay was confirmed (88%).[1]

Dr. Alan Partin, MD, PhD, Chairman of the Brady Urological Institute and Urologist-in-Chief at Johns Hopkins Hospital comments,

"The DOCUMENT study validates the three-gene epigenetic assay as a better predictor of risk for the presence of occult cancer than any other factor in the clinic today. Results from this study provide further clinical evidence that the epigenetic test delivers actionable information to help guide urologists on the decision for repeat prostate biopsy."

"DOCUMENT was a pivotal validation study, demonstrating that the test's high negative predictive value and odds ratio are robust and reproducible in different cohorts of patients," stated Dr. Epstein. "The importance of this blinded, multicentered study is that it validated the performance of the test using predetermined analytical cutoff values in a population of U.S. patients undergoing routine PSA screening for prostate cancer."

quote:

lordonehope schreef op 2 oktober 2014 17:45:

Het is een zielige vertoning aan het worden. Van belgisch trots naar lelijke eendje in de biovijver. Ik moet nog zien of dit nog wel goed komt.

quote:

bioscience schreef op 3 oktober 2014 08:05:

[...]

Als ik jouw berichtgeving leest heb je geen vertrouwen , maar wil ze wel kopen op een lagere koers .
Duidelijk gevalletje van eigen belang dus . Koers naar beneden lullen in eigen belang . Helaas een veel voorkomend verschijnsel op alle chatboxen .

Hoe kan je het verzinnen . Van Belgisch trots naar lelijk eendje , terwijl het bedrijf zojuist een aantal belangrijke ontwikkelingen heeft bereikt .

quote:

Bio-marker schreef op 5 oktober 2014 19:48:

MDXHealth price target EUR 7.80:

"We start following MDXHealth with an initial share price target of EUR 7,80, reflecting a share price increase of 96% compared to the 3 October price of EUR 3,96.

- MDXHealth is undervalued at 4 Euro or a 140 million Euro.
- Its price is not consistent with conservative Cologuard royalty prospects (rate 3%) if the market adequately prices Exact Sciences (the company that developed and commercializes Cologuard). We attach a net present value of these future royalties that exceeds the full share price of MDXHealth (i.e. EUR 4,57 per share)
- Beyond the main scenario, the company has the potential for exponential growth in value of sales in its main product ConfirmMDX pick up and if new markets are commercialized.
-In case SNJ-Biostoxx "accelerating sales" or "sunshine scenario" would tend to materialize, we expect a take-over of the company by 2015 with take-over price at least in the range 10-15 Euros.
- Main short-term risks relate to the negative cash flow and probable need for a capital increase or credit line, as expenses are increasing with sales but timing of cash flows are uncertain (milestone payments, royalties, medicare repayments, etc). A small capital increase or a strategic stake by a large biotech or pharma company could reduce uncertainty on these issues.
- Short-run triggers for upward stock movement include: (i) news on Cologuard sales and forward guidance by Exact Sciences: if sales exceed 50.000 patients already in 2014, MDX may get milestone payments up to $ 2 million this year; it will also raise expectations about future royalty streams; (ii) increasing sales of ConfirmMDX reported on 4 November 2014; (iii) collection of outstanding reimbursements of performed test including by Medicare; (iv) announcement of new partnerships or launch of products outside the US.

www.snj-biostoxx.eu/mdx-health.html